Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.64 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | KLK7 | P49862 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348658 | 1.00 | PPARA (0.64) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL1101542 | 0.92 | PPARA (0.59) | PPARAPPARGCTSSKLK5KLK7 | |
| SCHEMBL955526 | 0.90 | PPARA (0.74) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL955527 | 0.90 | PPARA (0.74) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL1312604 | 0.90 | PPARA (0.74) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL20905468 | 0.89 | PPARA (0.69) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL22390654 | 0.88 | PPARA (0.53) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL22390655 | 0.88 | PPARA (0.53) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL11901546 | 0.88 | PPARA (0.64) | PPARAPPARGCTSSKLK5CTSK | |
| SCHEMBL5249102 | 0.88 | PPARA (0.74) | PPARAPPARGCTSSKLK5CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935042-B1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | NOBO MEDICINE INC. (KR) | 2024-08-27 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | PPARA 3524/4885PPARG 4443/4885CTSS 271/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | PPARA 3166/4885PPARG 3594/4885CTSS 44/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | PPARA 3631/4885PPARG 3105/4885CTSS 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.